Notably, consistent with previous publications, our findings revealed a decreasing trend in the proportion of Black/African American participants over time, which dropped from 8% in trials initiated before 2013 to just 2% in those starting after 2015 [ 6 , 7 , 23 , 24 ].
← all excerpts
Reporting and representation of race and ethnicity data in phase III clinical trials for hematological malignancies.
1
—
—